HUTCHMED (China) Limited (HCM) Financial Ratios
21 years of historical data (2005–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: 111.01
P/FCF
N/A
—
5yr avg: 16.87
30Y Low16.9·High16.9
P/B Ratio
↓
1.43
↓-62% vs avg
5yr avg: 3.73
30Y Low1.9·High10.7
ROE
↑
45.3%
↓+7272% vs avg
5yr avg: -0.6%
30Y Low-43%·High45%
Debt/EBITDA
N/A
—
5yr avg: 3.24
30Y Low3.2·High10.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
HCM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
HUTCHMED (China) Limited trades at 4.0x earnings, 88% below its 5-year average of 33.6x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 82%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.8B | $2.3B | $2.5B | $3.1B | $2.5B | $5.6B | $4.5B | $3.3B | $3.1B | $4.9B | $1.6B |
| Enterprise Value | $1.8B | $2.4B | $2.5B | $3.0B | $2.2B | $5.2B | $4.3B | $3.3B | $3.0B | $4.8B | $1.6B |
| P/E Ratio → | 3.95 | 5.13 | 65.50 | 30.18 | — | — | — | — | — | — | 138.47 |
| P/S Ratio | 3.26 | 4.23 | 3.99 | 3.76 | 5.87 | 15.62 | 19.61 | 16.29 | 14.33 | 20.17 | 7.53 |
| P/B Ratio | 1.43 | 1.86 | 3.26 | 4.23 | 3.93 | 5.35 | 8.61 | 10.67 | 7.44 | 10.03 | 7.98 |
| P/FCF | — | — | — | 16.87 | — | — | — | — | — | — | — |
| P/OCF | — | — | 5061.35 | 14.36 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
HCM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 4.28 | 3.89 | 3.52 | 5.20 | 14.67 | 18.74 | 15.86 | 14.05 | 19.95 | 7.43 |
| EV / EBITDA | — | — | — | 111.01 | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | 160.59 | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | 15.81 | — | — | — | — | — | — | — |
HCM Profitability
Margins and return-on-capital ratios measuring operating efficiency
HUTCHMED (China) Limited earns an operating margin of -10.0%. Operating margins have compressed from 2.2% to -10.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. Return on equity of 45.3% is exceptionally high.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.7% | 38.7% | 44.6% | 54.1% | 27.0% | 27.5% | 17.3% | 21.8% | 32.8% | 27.1% | 27.7% |
| Operating Margin | -10.0% | -10.0% | -6.9% | 2.2% | -96.1% | -92.2% | -87.1% | -74.6% | -43.3% | -22.1% | -21.6% |
| Net Profit Margin | 83.3% | 83.3% | 6.0% | 12.0% | -84.6% | -54.7% | -55.2% | -51.7% | -34.9% | -11.1% | 5.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 45.3% | 45.3% | 5.0% | 14.6% | -43.0% | -25.0% | -30.2% | -29.2% | -16.7% | -7.8% | 7.6% |
| ROA | 30.3% | 30.3% | 3.0% | 8.7% | -30.0% | -18.6% | -21.1% | -21.3% | -13.2% | -5.7% | 4.1% |
| ROIC | -4.1% | -4.1% | -5.2% | 3.1% | -58.5% | -48.1% | -54.4% | -39.6% | -17.7% | -13.0% | -22.2% |
| ROCE | -4.7% | -4.7% | -4.9% | 2.4% | -47.2% | -40.4% | -43.3% | -38.3% | -19.7% | -14.4% | -23.6% |
HCM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $27M ($98M total debt minus $71M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.08 | 0.12 | 0.12 | 0.04 | 0.04 | 0.07 | 0.11 | 0.07 | 0.07 | 0.28 |
| Debt / EBITDA | — | — | — | 3.24 | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.02 | -0.08 | -0.27 | -0.45 | -0.33 | -0.38 | -0.28 | -0.14 | -0.11 | -0.11 |
| Net Debt / EBITDA | — | — | — | -7.43 | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | -1.06 | — | — | — | — | — | — | — |
| Interest Coverage | -19.05 | -19.05 | -15.22 | 24.21 | -628.48 | -363.43 | -252.37 | -136.00 | -84.88 | -35.79 | -28.02 |
HCM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
HUTCHMED (China) Limited's current ratio of 4.96x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.72x to 4.96x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.96 | 4.96 | 2.83 | 2.72 | 2.37 | 3.89 | 3.35 | 2.80 | 4.33 | 4.13 | 1.76 |
| Quick Ratio | 4.83 | 4.83 | 2.70 | 2.60 | 2.21 | 3.77 | 3.23 | 2.66 | 4.19 | 4.02 | 1.62 |
| Cash Ratio | 4.33 | 4.33 | 2.22 | 2.20 | 1.78 | 3.25 | 2.75 | 1.92 | 3.52 | 3.43 | 1.09 |
| Asset Turnover | — | 0.31 | 0.49 | 0.65 | 0.41 | 0.26 | 0.31 | 0.44 | 0.40 | 0.40 | 0.63 |
| Inventory Turnover | 8.20 | 8.20 | 6.92 | 7.65 | 5.49 | 7.22 | 9.54 | 9.88 | 11.69 | 14.91 | 12.19 |
| Days Sales Outstanding | — | 98.11 | 97.15 | 65.53 | 108.47 | 151.41 | 76.64 | 137.48 | 74.75 | 86.63 | 82.00 |
HCM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
HUTCHMED (China) Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 25.3% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | 3.5% | 1.8% | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 25.3% | 19.5% | 1.5% | 3.3% | — | — | — | — | — | — | 0.7% |
| FCF Yield | — | — | — | 5.9% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 1.4% | 0.3% | 1.9% | 0.5% | 0.3% | 0.0% | 0.2% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 1.4% | 0.3% | 5.4% | 2.3% | 0.3% | 0.0% | 0.2% | 0.0% | 0.0% |
| Shares Outstanding | — | $175M | $175M | $174M | $169M | $159M | $140M | $133M | $133M | $123M | $120M |
Peer Comparison
Compare HCM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 HCMYou | $2B | 4.0 | — | — | 38.7% | -10.0% | 45.3% | -4.1% | — |
 ZLAB | $2B | -11.4 | — | — | 58.5% | -48.6% | -22.6% | -41.7% | — |
 LEGN | $5B | -17.5 | — | — | 60.3% | -13.3% | -29.1% | -12.7% | — |
 CAN | $208M | -0.7 | — | — | 7.8% | -21.2% | -59.8% | -24.9% | — |
 ABBV | $383B | 91.4 | 15.8 | 21.5 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 MRK | $281B | 15.6 | 10.8 | 22.8 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 BMY | $110B | 15.7 | 8.9 | 8.6 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 EXEL | $13B | 18.7 | 14.3 | 15.6 | 96.4% | 37.6% | 35.5% | 32.1% | 0.2 |
 INCY | $20B | 15.3 | 11.6 | 14.5 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
 RCUS | $2B | -7.4 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 AZN | $271B | 26.7 | 15.2 | 23.1 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 21 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
HCM — Frequently Asked Questions
Quick answers to the most common questions about buying HCM stock.
What is HUTCHMED (China) Limited's P/E ratio?
HUTCHMED (China) Limited's current P/E ratio is 4.0x. The historical average is 59.8x.
What is HUTCHMED (China) Limited's ROE?
HUTCHMED (China) Limited's return on equity (ROE) is 45.3%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -8.6%.
Is HCM stock overvalued?
Based on historical data, HUTCHMED (China) Limited is trading at a P/E of 4.0x. Compare with industry peers and growth rates for a complete picture.
What are HUTCHMED (China) Limited's profit margins?
HUTCHMED (China) Limited has 38.7% gross margin and -10.0% operating margin.